Sort
15,273 grants matching “antimicrobial resistance”
Enhancing Undergraduate Research: Genome Data Mining and Laboratory Experimentation to Reveal the Fungal Agglutinin-Like Sequence Family
$475,800Lois L. Hoyer · University Of Illinois At Urbana-Champaign · R15 · FY2019 · DE
Identification of Pathways that can be Targeted for the Development of Novel Therapies for MRSA
$475,797Eleftherios Mylonakis · Massachusetts Eye And Ear Infirmary · P01 · FY2014 · AI
Infection-Dependent Vulnerabilities of Gram-negative Bacterial Pathogens
$475,749Corrella Detweiler · University Of Colorado · R01 · FY2024 · AI
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis
$475,680P. Worth Longest · Virginia Commonwealth University · R01 · FY2021 · HD
Persistent H. influenzae in COPD - virulence, vaccines and antibiotic resistance
$475,643Timothy F Murphy · State University Of New York At Buffalo · R01 · FY2014 · AI
The transcriptional circuitry controlling biofilm development in Candida albicans
$475,560Alexander D Johnson · University Of California, San Francisco · R01 · FY2017 · AI
A Randomized Controlled Trial of a Diagnostic Stewardship Intervention to Reduce Inappropriate Antibiotic Use for Urinary Tract Infections in Primary Care
$475,534Larisa Grigoryan · Baylor College Of Medicine · R01 · FY2024 · HS
Identification of novel secondary metabolites produced by symbiotic Proteobacte
$475,202Jon Clardy · University Of Wisconsin-Madison · U19 · FY2018 · AI
Identification of novel secondary metabolites produced by symbiotic Proteobacte
$475,202Jon Clardy · University Of Wisconsin-Madison · U19 · FY2016 · AI
Identification of novel secondary metabolites produced by symbiotic Proteobacte
$475,202Jon Clardy · University Of Wisconsin-Madison · U19 · FY2017 · AI
Lung-resident antibacterial heterotypic immunity
$475,147Joseph P Mizgerd · Boston University Medical Campus · R01 · FY2022 · AI
Metabolomics driven discovery of drug leads from symbiotic bacteria
$475,093David R Andes · University Of Wisconsin-Madison · U19 · FY2016 · AI
WE RECENTLY DEVELOPED SELF-DESTRUCTING SALMONELLA STRAINS THAT HAVE SUPERIOR ATTRIBUTES TO DISPLAY AT HIGH LEVELS MICROBE ASSOCIATED MOLECULAR PATTERNS (MAMPS) NATURALLY OR AFTER CELL DAMAGE TO EFFICIENTLY INDUCE INNATE IMMUNITY EFFECTORS TO AUGMENT THE ABILITY OF SUBUNIT AND LIVE VACCINES TO INDUCE PROTECTIVE IMMUNITY AGAINST CHALLENGES WITH PATHOGENS. WE RECENTLY DETERMINED THAT ADMINISTRATION OF SOME OF THESE SELF-DESTRUCTING ATTENUATED ADJUVANT SALMONELLA (SDAAS) STRAINS IN OVO TO 18-DAY OLD CHICK EMBRYOS PERMITTED NORMAL LEVELS OF HATCHABILITY. WE THEREFORE PROPOSE, TO OPTIMIZE SDAAS STRAINS TO STIMULATE PRODUCTION OF A SUSTAINED INNATE IMMUNITY AND BE SAFELY USED FOR IN OVO INOCULATION OF EMBRYONATED EGGS WITHOUT REDUCTION IN HATCHABILITY OR IN WEIGHT GAIN AND FEED CONVERSION EFFICIENCY OF THE HATCHED CHICKS. WE WILL THEN PROCEED TO DETERMINE WHETHER SUCH IN OVO SDAAS STRAIN ADMINISTRATION (IN COMPARISON TO ADMINISTERING BUFFERED SALINE) CAN REDUCE INFECTION AND COLONIZATION OFDAY-OF-HATCH CHICKS BY SALMONELLA, APEC/EXPEC, CAMPYLOBACTER JEJUNI, LISTERIA MONOCYTOGENES AND CLOSTRIDIUM PERFRINGENS. THE LAST OBJECTIVE IS TO ESTABLISH THE BASIS FOR THE OBSERVED RESULTS. SUCCESS IN THESE ENDEAVORS WILL ENSURE THE BETTER HEALTH OF CHICKENS TO ENABLE BETTER GROWTH PERFORMANCE, ENHANCE THE SAFETY OF POULTRY FOR HUMAN CONSUMPTION AND REDUCE THE USE OF ANTIMICROBIAL DRUGS DURING POULTRY REARING AND THUS REDUCE THE SELECTIVE PRESSURE FOR EXPANSION IN DRUG-RESISTANT BACTERIAL PATHOGENS.
$474,984University Of Florida · · FY2021 · National Institute of Food and Agriculture
Synergistic killing of bacterial pathogens by histones
$474,960Albert Siryaporn · University Of California-Irvine · R01 · FY2025 · AI
Synergistic killing of bacterial pathogens by histones
$474,960Albert Siryaporn · University Of California-Irvine · R01 · FY2023 · AI
Synergistic killing of bacterial pathogens by histones
$474,960Albert Siryaporn · University Of California-Irvine · R01 · FY2024 · AI
Function of MVFR in Pseudomonas Aeruginosa Virulence
$474,950Laurence G Rahme · Massachusetts General Hospital · R56 · FY2012 · AI
Synthesis and Chemical Biology of Bioactive Natural Products
$474,947Joshua G. Pierce · North Carolina State University Raleigh · R35 · FY2021 · GM
Synthesis and Chemical Biology of Bioactive Natural Products
$474,947Joshua G. Pierce · North Carolina State University Raleigh · R35 · FY2024 · GM
Synthesis and Chemical Biology of Bioactive Natural Products
$474,947Joshua G. Pierce · North Carolina State University Raleigh · R35 · FY2023 · GM
Synthesis and Chemical Biology of Bioactive Natural Products
$474,947Joshua G. Pierce · North Carolina State University Raleigh · R35 · FY2022 · GM
Synthesis and Chemical Biology of Bioactive Natural Products
$474,947Joshua G. Pierce · North Carolina State University Raleigh · R35 · FY2025 · GM
TANA II
$474,936Thomas M Lietman · University Of California, San Francisco · U10 · FY2012 · EY
Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics
$474,777David Elihu Greenberg · Ut Southwestern Medical Center · R33 · FY2016 · AI
Environmental hygiene strategies to decrease the burden of antibiotic-resistant organisms in Intensive Care Unit SINKs (ICU SINK)
$474,732Jennie H Kwon · Washington University · R01 · FY2024 · HS